Cartesian Therapeutics, Inc.

AbbVie is taking a deep dive into CAR-T therapies for autoimmune diseases with its acquisition of privately owned Capstan Therapeutics for up to $2.1bn, an investment that both bolsters its autoimmune

Cartesian Therapeutics is banking on both positive mid-stage data for Descartes-08 as well as a manufacturing process designed to cut down on logistical hurdles and toxicity in order to make its CAR-T

The number of biopharmaceutical company initial public offerings in the US dropped considerably from the first quarter to the second quarter, but with 12 IPOs during the first half of 2024 the market

Cartesian Therapeutics, Inc. has positive data from a Phase IIb trial testing Descartes-08, an autologous mRNA-engineered chimeric antigen receptor T-cell (CAR-T) therapy directed against the B-cell